These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26125583)

  • 21. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010.
    Thoon KC; Chong CY; Tee NW
    Int J Infect Dis; 2012 Mar; 16(3):e209-15. PubMed ID: 22281191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales.
    Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
    Clin Infect Dis; 2013 Mar; 56(5):633-40. PubMed ID: 23175560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ; McIntosh ED; Reinert RR
    Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland.
    Clarke SC; Jefferies JM; Smith AJ; McMenamin J; Mitchell TJ; Edwards GF
    J Clin Microbiol; 2006 Apr; 44(4):1224-8. PubMed ID: 16597842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    De Wals P; Lefebvre B; Markowski F; Deceuninck G; Defay F; Douville-Fradet M; Landry M
    Vaccine; 2014 Mar; 32(13):1501-6. PubMed ID: 24486346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB; Dalby T; Weinberger DM; Benfield T; Mølbak K; Slotved HC; Suppli CH; Konradsen HB; Valentiner-Branth P
    Clin Infect Dis; 2014 Oct; 59(8):1066-73. PubMed ID: 25034421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease.
    Yildirim I; Shea KM; Little BA; Silverio AL; Pelton SI;
    Pediatrics; 2015 Mar; 135(3):495-503. PubMed ID: 25647674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive Streptococcus pneumoniae isolates in a nationwide surveillance study in Lebanon.
    Hanna-Wakim R; Chehab H; Mahfouz I; Nassar F; Baroud M; Shehab M; Pimentel G; Wasfy M; House B; Araj G; Matar G; Dbaibo G;
    Vaccine; 2012 Dec; 30 Suppl 6():G11-7. PubMed ID: 23228352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Giangaspro E; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C;
    Pediatr Infect Dis J; 2013 Jun; 32(6):656-61. PubMed ID: 23249906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of capsular switch on invasive pneumococcal disease incidence in a vaccinated population.
    Temime L; Boelle PY; Opatowski L; Guillemot D
    PLoS One; 2008 Sep; 3(9):e3244. PubMed ID: 18802466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.
    Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A
    Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation.
    dos Santos SR; Passadore LF; Takagi EH; Fujii CM; Yoshioka CR; Gilio AE; Martinez MB
    Vaccine; 2013 Dec; 31(51):6150-4. PubMed ID: 23747454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine.
    Talbot TR; Poehling KA; Hartert TV; Arbogast PG; Halasa NB; Mitchel E; Schaffner W; Craig AS; Edwards KM; Griffin MR
    Clin Infect Dis; 2004 Sep; 39(5):641-8. PubMed ID: 15356776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use.
    Pilishvili T; Zell ER; Farley MM; Schaffner W; Lynfield R; Nyquist AC; Vazquez M; Bennett NM; Reingold A; Thomas A; Jackson D; Schuchat A; Whitney CG
    Pediatrics; 2010 Jul; 126(1):e9-17. PubMed ID: 20547641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program.
    Watson M; Roche P; Bayley K; Bell JM; Collignon P; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Smith HV; Brown M; Stylianopoulos J; Turnidge J
    Commun Dis Intell Q Rep; 2004; 28(4):455-64. PubMed ID: 15745392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Burden of paediatric invasive pneumococcal disease in Europe, 2005.
    McIntosh ED; Fritzell B; Fletcher MA
    Epidemiol Infect; 2007 May; 135(4):644-56. PubMed ID: 16959054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.